You have access
Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel – A Final Analysis of the Prosty II Trial
PIRKKO-LIISA KELLOKUMPU-LEHTINEN, TIMO MARTTILA, ANTTI JEKUNEN, PETTERI HERVONEN, KATARIINA KLINTRUP, VESA KATAJA, TAPIO UTRIAINEN, MARJAANA LUUKKAA, MARKKU LESKINEN, KALEVI PULKKANEN, ANNA-LIISA KAUTIO and TEPPO HUTTUNEN
Anticancer Research December 2020, 40 (12) 6915-6921; DOI: https://doi.org/10.21873/anticanres.14715